Qiagen (NYSE:QGEN – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 2.160- for the period, compared to the consensus earnings per share estimate of 2.120. The company issued revenue guidance of $2.0 billion-, compared to the consensus revenue estimate of 2.160.
Qiagen Stock Performance
QGEN traded down $0.09 during trading on Friday, reaching $45.42. 847,455 shares of the company were exchanged, compared to its average volume of 1,245,056. The stock has a market cap of $10.36 billion, a P/E ratio of 30.46, a PEG ratio of 3.19 and a beta of 0.40. The firm has a 50 day moving average of $42.85 and a 200 day moving average of $43.04. The company has a current ratio of 1.77, a quick ratio of 1.45 and a debt-to-equity ratio of 0.27. Qiagen has a 52 week low of $34.74 and a 52 week high of $46.55.
Qiagen (NYSE:QGEN – Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.03. The firm had revenue of $496.00 million during the quarter, compared to the consensus estimate of $495.45 million. Qiagen had a return on equity of 12.92% and a net margin of 3.75%. The firm’s revenue was down .2% on a year-over-year basis. During the same period in the prior year, the business earned $0.53 EPS. On average, sell-side analysts forecast that Qiagen will post 2.15 EPS for the current fiscal year.
Analysts Set New Price Targets
View Our Latest Stock Report on Qiagen
Qiagen Company Profile
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Read More
- Five stocks we like better than Qiagen
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- MarketBeat Week in Review – 8/5 – 8/9
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Quiet Period Expirations Explained
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.